Fitness effects of blaCTX-M-15-harbouring F2:A1:B- plasmids on their native Escherichia coli ST131 H30Rx hosts.


Journal

The Journal of antimicrobial chemotherapy
ISSN: 1460-2091
Titre abrégé: J Antimicrob Chemother
Pays: England
ID NLM: 7513617

Informations de publication

Date de publication:
28 10 2022
Historique:
received: 11 01 2022
accepted: 27 06 2022
pubmed: 27 7 2022
medline: 2 11 2022
entrez: 26 7 2022
Statut: ppublish

Résumé

To investigate the fitness effects of large blaCTX-M-15-harbouring F2:A1:B- plasmids on their native Escherichia coli ST131 H30Rx hosts. We selected five E. coli ST131 H30Rx isolates of diverse origin, each carrying an F2:A1:B- plasmid with the blaCTX-M-15 gene. The plasmid was eliminated from each isolate by displacement using an incompatible curing plasmid, pMDP5_cureEC958. WGS was performed to obtain complete chromosome and plasmid sequences of original isolates and to detect chromosomal mutations in 'cured' clones. High-throughput competition assays were conducted to determine the relative fitness of cured clones compared with the corresponding original isolates. We were able to successfully eliminate the F2:A1:B- plasmids from all five original isolates using pMDP5_cureEC958. The F2:A1:B- plasmids produced non-significant fitness effects in three isolates and moderate reductions in relative fitness (3%-4%) in the two remaining isolates. We conclude that F2:A1:B- plasmids pose low fitness costs in their E. coli ST131 H30Rx hosts. This plasmid-host fitness compatibility is likely to promote the maintenance of antibiotic resistance in this clinically important E. coli lineage.

Identifiants

pubmed: 35880751
pii: 6650071
doi: 10.1093/jac/dkac250
doi:

Substances chimiques

beta-Lactamases EC 3.5.2.6
Anti-Bacterial Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2960-2963

Subventions

Organisme : Czech Science Foundation
ID : 18-23532S
Organisme : Ministry of Health of the Czech Republic
ID : NU20J-05-00033
Organisme : Central European Institute of Technology
ID : LQ1601
Organisme : Internal Grant Agency of University of Veterinary Sciences Brno
ID : 209/2021/FVHE

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Jana Palkovicova (J)

Central European Institute of Technology, University of Veterinary Sciences Brno, Brno, Czech Republic.
Department of Biology and Wildlife Diseases, University of Veterinary Sciences Brno, Brno, Czech Republic.

Iva Sukkar (I)

Central European Institute of Technology, University of Veterinary Sciences Brno, Brno, Czech Republic.

Javier Delafuente (J)

Department of Microbiology, Hospital Universitario Ramon y Cajal (IRYCIS), Madrid, Spain.

Adam Valcek (A)

Central European Institute of Technology, University of Veterinary Sciences Brno, Brno, Czech Republic.
Microbial Resistance and Drug Discovery, VIB-VUB Centre for Structural Biology, VIB, Flanders Institute for Biotechnology, Brussels, Belgium.
Structural Biology Brussels, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Matej Medvecky (M)

Central European Institute of Technology, University of Veterinary Sciences Brno, Brno, Czech Republic.
Institute of Biodiversity, Animal Health and Comparative Medicine, University of Glasgow, Glasgow, UK.

Ivana Jamborova (I)

Central European Institute of Technology, University of Veterinary Sciences Brno, Brno, Czech Republic.

Ibrahim Bitar (I)

Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.

Minh-Duy Phan (MD)

Australian Infectious Diseases Research Centre, School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia.

Alvaro San Millan (A)

Centro Nacional de Biotecnologia-CSIC, Madrid, Spain.

Monika Dolejska (M)

Central European Institute of Technology, University of Veterinary Sciences Brno, Brno, Czech Republic.
Department of Biology and Wildlife Diseases, University of Veterinary Sciences Brno, Brno, Czech Republic.
Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Department of Clinical Microbiology and Immunology, Institute of Laboratory Medicine, The University Hospital Brno, Brno, Czech Republic.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH